Evonik's Pharma Lab Prize Meets a Takeover Standoff: Inside the 21.42 Euro Close
Published on 10/11/2026 at 03:02 | Editorial boerse-global.de
Evonik's stock ended Friday at 21.42 euros, up 1.7% on the day, after touching a fresh 52-week high of 21.62 euros intraday. That headline number tells only part of the story. Behind it sits a tangle of takeover intrigue, a foundation keeping its cards close, union pushback, and a pharma division quietly collecting awards while investors wait for the November 3 quarterly print.
The stock has climbed 60% since the start of the year, a run fueled less by operational results than by the prospect of a suitor circling. BASF, the Ludwigshafen-based chemicals giant, has been exploring a takeover of the Essen specialty chemicals group. Evonik rejected an initial offer of roughly 22.15 euros per share as too low, according to Reuters. A first BASF bid had already been turned down earlier, per dpa-AFX. Evonik confirmed receiving an unsolicited approach regarding a voluntary public takeover offer about two weeks ago, while stating that no talks were underway at that time.
The Foundation's Deliberate Silence
What happens next may hinge on RAG-Stiftung, Evonik's largest shareholder. The foundation's board of trustees met online Friday to discuss BASF's interest but declined to take a clear stance on whether to keep or sell its stake, according to Handelsblatt, citing people familiar with the matter. Instead, the foundation's position is that BASF and Evonik should first negotiate bilaterally. The meeting's contents and decisions officially remain confidential.
That reticence matters because the foundation's stance is seen as decisive for the specialty chemicals group's future. RAG-Stiftung confirmed to Reuters in late September that its charter permits reducing the stake, including a full sale, provided the board of trustees approves.
Should investors sell immediately? Or is it worth buying Evonik?
Political and Labor Headwinds
Not everyone welcomes a deal. Michael Vassiliadis, chairman of the IG BCE union, sent a letter to works councils at both companies openly questioning a complete sale of Evonik's stake by the foundation. He demanded clarity on how such a move would square with the foundation's established position, according to media reports. Meanwhile, the SPD parliamentary group in North Rhine-Westphalia's state legislature floated the idea of examining a direct stake by the state of NRW.
Pharma Wins and Pipeline Progress
Away from the takeover noise, Evonik's Health Care division is making its own headlines. On Wednesday, the company won the CPHI Pharma Award 2026 in the "Digital Transformation" category for its use of so-called Self Driving Labs. The recognition underscores Evonik's push to accelerate development processes in its pharma unit through automation.
The division also developed a biodegradable polymer platform serving as the basis for functional excipients for oral drug delivery under the EUDRAGIT brand. Evonik is making non-commercial lab quantities of the platform available to selected partners for joint development projects. Such efforts carry strategic weight, strengthening the group's position in higher-margin specialty business while traditional chemicals segments grapple with economic swings.
Analysts Reprice the Stock
The shifting landscape has prompted research desks to revise their views. On October 5, Berenberg upgraded the stock from "Sell" to "Hold" and raised its price target from 15.50 euros to 20.00 euros. Analyst Sebastian Bray cited BASF's interest as a potential floor under the shares. A day later, Parmantier & Cie maintained a "Hold" rating with a six-month price target of 20.50 euros.
Evonik's third-quarter 2026 results, due November 3, will give investors their first hard look at the operational side of the story. Until then, the question likely to dominate is whether BASF returns with an improved offer — or whether the numbers start calling the tune.
Ad
Evonik Stock: New Analysis - 11 October
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
